Integrated next-generation flow cytometry and sequencing to uncover the pathway of curability in multiple myeloma
Multiple myeloma (MM) represents a unique model for investigating cancer stem cells (CSCs), circulating tumor cells (CTCs), and mechanisms of malignant transformation and chemoresistance. Despite substantial improvement in the outcome of MM patients, the vast majority of patients eventually relapse and the disease remains largely incurable.
For patients who fail to achieve deep remissions, biological research targeting the ultra-resistant minimal residual disease (MRD) clone may allow us to understand the cellular mechanisms driving chemoresistance and design new therapies to overcome it.
- Reference: 680200
- Duration: 2016-2021
- Start date: September 1, 2016
- End date: August 31, 2021
- Funder: Comisión Europea
- Grant: € 1 468 606
- Nature of project: International
- Award year 2016
Need more information?
If you are interested in learning more about our research, please contact us